Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 679 Avalo Therapeutics, Inc. shares (Form 4)

Traded May 28, 2026 · Filed Jun 1, 2026

On May 28, 2026, Doyle Mittie (Chief Medical Officer) sold 679 Avalo Therapeutics, Inc. shares at US$16.00 for US$10,864 under a trading plan, leaving 47,122 shares. Filed Jun 1, 2026 (Form 4).

Sold: 679 shares
Price: US$16.00
Value: US$10,864
Holding after: 47,122 shares
Trading plan: Yes (Made under a plan set in advance)
Role: Chief Medical Officer

The filing in full

Date	Security	Transaction	Shares	Price	Holding after	Ownership
May 28, 2026	Common Stock	Option exercise	679	US$8.04	47,801	Direct
May 28, 2026	Common Stock	Sale	679	US$16.00	47,122	Direct

Source

View original at SEC

Related